Senior Executives

Experience: Carlos de Sousa has over 25 years of experience from executive positions within the global pharmaceutical and biotech market, including experience from business development, acquisitions, global marketing and clinical development. Prior to joining Immunicum, Carlos held senior executive positions within Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron Pharmaceuticals and most recently as Chief Business Officer at Zealand Pharma in Denmark.

Ongoing engagements: –

Past engagements during the last five (5) years: –

Experience: Prior to joining Immunicum, Peter was working as Global Clinical Program Lead for oncology and Senior Director of Clinical Sciences at Glenmark Pharmaceuticals R&D in London, where he was responsible of the unit for clinical Oncology (immune oncology assets) from the start-up phase to full operational phase I/II protocol development. Prior to that role, he was Director and Head of clinical Development and Human Transplantation Research, a position with global scope, and a member of management of the Life Science department at Danone Research in Paris. Before this, he was Clinical Research and Develeopment Leader within the global early immunotherapy development at GlaxoSmithKline Vaccines in Rixensart, Belgium, and Clinical Research Senior Medical Scientist, Global Development, Haematology/Oncology at AMGEN in U.K.

Ongoing engagements: –

Past engagements during the last five (5) years: –

Experience: Michaela Gertz most recently was CFO & Investor Relations Manager at PledPharma AB, a drug development company based in Stockholm. Ms. Gertz was instrumental in PledPharma’s IPO in 2011 and subsequent fund-raising efforts. Prior to that, Ms. Gertz spent three years as Head of Investor Relations and Financing at Accelerator Nordic AB. Before joining the life sciences industry, Ms. Gertz worked in finance and private equity at ITP Invest AB and Handelsbanken.

Ongoing engagements: –

Past engagements during the last five (5) years: –

Experience: Alex Karlsson-Parra, MD, PhD has over 20 years of experience within transplantation immunology. In addition to his position as Co-Founder and CSO at Immunicum, he also serves as Associate Professor in Clinical Immunology at Uppsala University, Uppsala, Sweden, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman of the Swedish Expert Group for Clinical immunology. Dr. Karlsson-Parra was awarded the Athena Prize, the Swedish healthcare´s most prestigious award for clinical research, in 2014. Prior to his current positions, he served as Associate Professor and Senior Physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg, Sweden and Uppsala University Hospital, Sweden.

Ongoing engagements: –

Past engagements during the last five (5) years: Board member of Immunicum.

Experience: Sharon Longhurst has over 15 years in leading CMC efforts in small and medium sized organization. Sharon Longhurst joins Immunicum from her previous position as Senior CMC Manager at Akari Therapeutics, where she was responsible for all aspects of CMC, including clinical supply and distribution. Prior to that, Sharon spent 5 years as Principal Consultant of CMC at Parexel Consulting. From 2005–2011, she was a Pharmaceutical Assessor at MHRA in London in the biologics/biotechnology unit and provided national and EU scientific advice for Advance Therapy Medicinal Products (ATMPs) for cell and gene therapy.

Ongoing engagements: –

Past engagements during the last five (5) year: –

Experience: Margareth Jorvid has over 30 years’ experience in Regulatory Affairs for pharmaceuticals and has worked at the Medical Products Agency (MPA), as well as in large and small pharmaceutical companies such as Roussel Nordiska, Hoechst Marion Roussel (Stockholm and Paris, France) and Neopharma. Since 2006, consultant in regulatory affairs and quality assurance for pharmaceuticals and medical devices, as CEO of Methra Uppsala AB, LSM group. She is a Fellow and Honorary Life Member of TOPRA (The Organisation for Professionals in Regulatory Affairs), board member and TOPRA President 2005-2006.

Ongoing engagements: –

Past engagements during the last five (5) years: –

Experience: Sijme Zeilemaker joins Immunicum having most recently served as Director Business Development at InteRNA Technologies where he supported the preclinical oncology company in connecting with pharmaceutical and biotechnology companies, licensing technologies and exploring grant opportunities. Sijme also served as Head of Business for 2-BBB Medicines and Business Development Manager for to-BBB technologies where he provided partnering support and attracted funding.

Ongoing engagements: –

Past engagements during the last five (5) years: –